Reporting to the VP of Translational Science, the Translational Scientist plans, designs, coordinates and oversees implementation and management of preclinical studies on the critical path for development programs, performs data analysis, interpretation, and presentation of results and may contribute to clinical study synopses/protocols, Investigator Brochures, regulatory communications, preclinical study reports, and data collection systems.
HAYA Therapeutics is a precision RNA-based therapeutics company that discovers and develops innovative genomic medicines for the treatment of fibrosis and other serious health conditions associated with aging. The company's discovery engine focuses on long non-coding RNAs (lncRNAs) within the “dark matter” of the human genome -- key tissue and cell-specific drivers of multiple disease processes including fibrosis -- to identify novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments.
Headquartered in Lausanne, Switzerland with laboratory facilities in San Diego, USA, HAYA is a rapidly growing company led by a world-class team and supported by a strong investor consortium.
HAYA Therapeutics is an Equal Opportunity Employer committed to fostering a diverse, inclusive, and equitable workplace where all individuals feel valued and empowered. We provide equal employment opportunities to all qualified applicants and employees without regard to race, color, religion, sex (including pregnancy, sexual orientation, gender identity, or gender expression), national origin, ancestry, age, marital or familial status, veteran status, disability, genetic information, or any other characteristic protected by applicable federal, state, or local laws.
We prohibit discrimination and harassment of any kind and are committed to ensuring fair and equitable treatment in all aspects of recruitment, hiring, promotion, compensation, benefits, training, and career development.
At HAYA, we believe that diversity of thought, experience, and background drives innovation and strengthens our mission to transform patient care through cutting-edge RNA-based therapeutics.
HAYA Therapeutics is a precision RNA-based therapeutics company that discovers and develops innovative genomic medicines for the treatment of fibrosis and other serious health conditions associated with aging. The company's discovery engine focuses on long non-coding RNAs (lncRNAs) within the “dark matter” of the human genome -- key tissue and cell-specific drivers of multiple disease processes including fibrosis -- to identify novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments.
Headquartered in Lausanne, Switzerland with laboratory facilities in San Diego, USA, HAYA is a rapidly growing company led by a world-class team and supported by a strong investor consortium.